Q4 results and sector backdrop

Haemonetics (HAE) reported fourth quarter earnings with sales of US$346.35 million and a net loss of US$20.15 million, while the broader medical devices sector experienced a sell off driven by macro factors.

At a share price of US$54.37, Haemonetics has a 1 day share price return of 3.23%, while its year to date share price return of 32.02% and 1 year total shareholder return of 20.06% reflect pressure building over a longer period as the market weighs margin compression, sector wide selling and upcoming investor communication.

If Haemonetics's recent swings have you reassessing healthcare exposure, it can help to see what else is moving in related niches such as 35 healthcare AI stocks

With Haemonetics trading at US$54.37 and sitting well below some external valuation markers, yet facing shrinking margins and a recent quarterly loss, are you looking at a genuine opportunity or a stock where the market already recognises potential future growth?

Most Popular Narrative: 37.4% Undervalued

Haemonetics' most followed narrative pegs fair value at $86.90, well above the last close of $54.37, framing a sizable gap for investors to assess.

Enterprise-wide portfolio transformation highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions is driving substantial gross and operating margin expansion (guidance of 26–27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.

Curious what earnings path and margin profile need to materialize to support that fair value? The narrative leans on a tight mix of projected revenue growth, rising profitability and a future earnings multiple that still sits below broader industry levels.

Result: Fair Value of $86.90 (UNDERVALUED)

However, this hinges on Haemonetics avoiding setbacks in its concentrated NexSys, TEG and VASCADE portfolio, as well as managing tougher competition in interventional technologies.

Another View: Multiples Paint A Tighter Picture

The DCF work suggests Haemonetics is trading about 43.5% below an estimated fair value of $96.20, yet the market is pricing the stock at a P/E of 26x versus 23.9x for the US Medical Equipment industry and 24.5x for peers. The fair ratio sits even higher at 30.2x. That combination of discount to cash flow and premium to current peers raises a simple question: is this a mispriced chance or just extra risk if earnings do not keep pace?

Next Steps

Conflicted about whether this story skews more positive or cautious? Use the data as a prompt to move quickly and form your own take with 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities that fit your style, so keep building your watchlist with targeted ideas that match your goals.

• Zero in on quality at a discount by scanning companies that currently screen as compelling with the 51 high quality undervalued stocks.
• Prioritise resilience and sleep-better-at-night holdings by checking out the 72 resilient stocks with low risk scores.
• Spot potential future standouts before the crowd by reviewing the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.